by Asa Elmore | May 14, 2020 | News, Press Releases
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery,...
by Asa Elmore | May 11, 2020 | News, Press Releases
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated...
by Asa Elmore | Apr 27, 2020 | News, Presentations
Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 Dr. Wendel Naumann of The Levine Cancer Institute,...
by Asa Elmore | Apr 27, 2020 | Events, News, Presentations
Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation Download Presentation CLICK...
by Asa Elmore | Apr 27, 2020 | Events, News, Presentations, Press Releases
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer –...
